Wed, Jul 23, 2014, 8:50 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Forest Laboratories Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • shano58 shano58 Jul 10, 1998 11:13 AM Flag

    Patent expiration & p/e

    If you all would read the May 30 press release,
    you would know that it does not matter the patient
    date for Celexa. In the press release, Forest
    announced a marketing agreement for the Big Bother of
    Celexa. It is "the active enantiomer of Celexa, which
    will enter clinical studies later this year and is
    patented until the year 2009." If Celexa sells anything
    like it has in Europe, Forest will transfer the Celexa
    sales to the new agent before the patient expires. This
    has been done successfully by all the pharmaceutical
    companies.

    The anti-depressant market in the U.S. is close to 5
    billion dollars. Three of the top ten most prescribed
    drugs in the U.S. are anti-depressants (Prozac #2,
    Zoloft #5, Paxil #7 I think?). When Forest reaches a 10%
    market share with Celexa, it will DOUBLE the size of the
    company's sales.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Gilead Sciences Inc.
NasdaqGSWed, Jul 23, 2014 3:59 PM EDT